Futibatinib (TAS-120), an irreversible inhibitor of FGFR1–4, has demonstrated promising antitumor activity in various cancer cell lines harboring FGFR alterations, including BC with FGFR3 fusions [72]. This evidence concerns the gene FGFR3 and cancer.